PL EN


Preferences help
enabled [disable] Abstract
Number of results
2014 | 27 | 1 | 32-36
Article title

An analysis of potential costs of adverse events based on Drug Programs in Poland. Pulmonology focus

Content
Title variants
Languages of publication
EN
Abstracts
EN
The project was performed within the Polish Society for Pharmacoeconomics (PTFE). The objective was to estimate the potential costs of treatment of side effects, which theoretically may occur as a result of treatment of selected diseases. We analyzed the Drug Programs financed by National Health Fund in Poland in 2012 and for the first analysis we selected those Programs where the same medicinal products were used. We based the adverse events selection on the Summary of Product Characteristics of the chosen products. We extracted all the potential adverse events defined as frequent and very frequent, grouping them according to therapeutic areas. This paper is related to the results in the pulmonology area. The events described as very common had an incidence of ≥ 1/10, and the common ones ≥ 1/100, <1/10. In order to identify the resources used, we performed a survey with the engagement of clinical experts. On the basis of the collected data we allocated direct costs incurred by the public payer. We used the costs valid in December 2013. The paper presents the estimated costs of treatment of side effects related to the pulmonology disease area. Taking into account the costs incurred by the NHF and the patient separately e calculated the total spending and the percentage of each component cost in detail. The treatment of adverse drug reactions generates a significant cost incurred by both the public payer and the patient.
Publisher
Year
Volume
27
Issue
1
Pages
32-36
Physical description
Dates
published
1 - 6 - 2014
received
17 - 3 - 2014
accepted
24 - 3 - 2014
online
30 - 5 - 2014
References
  • 1. Agencja Oceny Technologii Medycznych: Wytyczne oceny technologii medycznych (HTA) wersja 2.1. Warszawa, kwiecień 2009. Online: http://www.aotm.gov.pl/assets/files/wytyczne_hta/2009/Wytyczne_HTA_pl_MS_29052009.pdf, access: 2014.01.19
  • 2. Allue N., Chiarello P., Bernal Delgado E., Castells X., Giraldo P., Martinez N., Sarsanedas E., Cots F.: Impacto economico de los eventos adversos en los hospitales espanoles a partir del Conjunto Minimo Basico de Datos” Assessing the economic impact of adverse events in Spanish hospitals by using administrative data. Gaceta Sanitaria, 2014, 1-2, s. 48-54.[Crossref]
  • 3. Gautier S., Bachelet H., Bordet R., Caron J.: The cost of adverse drug reactions. Expert Opin. Pharmacother. 2003, 4, 3, s. 319-326.
  • 4. Pattanaik S., Dhamija P., Malhotra S., Sharma N., Pandhi P.: Evaluation of cost of treatment of drug-related events in a tertiary care public sector hospital in Northen India: a prospective study. British Journal of Clinical Pharmacology. 2009, 67, 3, s. 363-369.
  • 5. Pliki parametryzujące. online: http://jgp.uhc.com.pl/doc/index.html, Access: 2014.01.06.
  • 6. Rozporządzenie Ministra Zdrowia z 2 kwietnia 2012 roku w sprawie minimalnych wymagań jakie muszą spełniać analizy uwzględnione we wnioskach o objęcie refundacją i ustalenie urzędowej ceny zbytu oraz podwyższenie urzędowej ceny zbytu leku, środka spożywczego specjalnego przeznaczenia, wyrobu medycznego, ktore nie mają odpowiednika refundowanego w danym wskazaniu. Dz. U. 2012, poz. 388.
  • 7. Szkultecka-Debek M., Drozd M., Wiśniewska N., Drozd K.: Adverse events (AE) cost assessed in Poland based on existing Drug programs - methodology of the project. Curr. Issues Pharm. Med. Sci. 2013, 26, 4, p. 422-424.
  • 8. Ustawa z dn. 12 maja 2011 roku o refundacji lekow, środkow spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobow medycznych. Dz. U. 2011 nr 122 poz. 696 z poźn. zm.
  • 9. Wiśniewska N., Szkultecka-Dębek M., Owczarek W., Paluchowska E., Jahnz-Rożyk K.: The direct costs of drug-induced skin reactions in Poland. Value in Health, 16, 7, 2013, s. A696.
  • 10. Załącznik do Obwieszczenia Ministra Zdrowia z dnia 25 października 2013 r. w sprawie wykazu refundowanych lekow, środkow spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobow medycznych na dzień 1 listopada 2013 r. http://www2.mz.gov.pl/wwwmz/index?mr=q491&ms=383&ml=pl&mi=383&mx=0&mt=&my=419&ma=32785, access: 2013.11.04.
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.-psjd-doi-10_2478_cipms-2014-0009
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.